Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy

• Published in: Archives of Endocrinology and Metabolism 2018-03, Vol.62 (2), p.149-156
• Main Authors: Súss, Shirlei Kugler Aiçar, Mesa, Cleo Otaviano, Carvalho, Gisah Amaral de, Miasaki, Fabíola Yukiko, Chaves, Carolina Perez, Fuser, Dominique Cochat, Corbo, Rossana, Momesso, Denise, Bulzico, Daniel A., Graf, Hans, Vaisman, Fernanda
• Format: Article
• Language: English
• Subjects: low activity; Original; radioiodine ablation; Thyroid carcinoma
• ISSN: 2359-3997; 2359-4292; 2359-4292
• DOI: 10.20945/2359-3997000000025

ABSTRACT Objective To retrospectively evaluate the outcomes of patients with low and intermediate risk thyroid carcinoma treated with total thyroidectomy (TT) and who did not undergo radioiodine remnant ablation (RRA) and to compare them to patients receiving low dose of iodine (30 mCi). Subjects and methods A total of 189 differentiated thyroid cancer (DTC) patients treated with TT followed by 30mCi for RRA or not, followed in two referral centers in Brazil were analyzed. Results From the 189 patients, 68.8% was ATA low-risk, 30.6% intermediate and 0.6% high risk. Eighty-seven patients underwent RRA and 102 did not. The RRA groups tended to be younger and had a higher frequency of extra-thyroidal extension (ETE). RRA did not have and impact on response to initial therapy neither in low (p = 0.24) nor in intermediate risk patients (p = 0.66). It also had no impact on final outcome and most patients had no evidence of disease (NED) at final follow-up. Recurrence/persistence of disease was found in 1.2% of RRA group and 2% in patients treated only with TT (p = 0.59). Conclusions Our study shows that in low and intermediate-risk patients, RRA with 30 mCi seems to have no major advantage over patients who did not undergo RRA regarding response to initial therapy in each risk group and also in long term outcomes.